Floatz logo

Hydroxypropyl-Beta-Cyclodextrin

Niemann-Pick Disease, Type C1

Cyclo Therapeutics, Inc.Phase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Niemann-Pick Disease, Type C1 cohort.

Asset / SponsorPhaseRating
2-HYDROXYPROPYL BETA-CYCLODEXTRIN (DS 4.2)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/2CCC
Vorinostat
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1/2CCC
LITHIUM, ELEMENTAL
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Early Phase 1C

Same molecule, other indications

Hydroxypropyl-Beta-Cyclodextrin is also rated in:

Alzheimer diseaseDormant
CCC
Indicative ·
51 / 100
View asset →
ischemic strokeDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →